Canada-based PharmaTher has received US Food and Drug Administration (FDA) approval for its ketamine therapy for surgical ...

The latest announcement is out from PharmaTher Holdings Ltd ( ($TSE:PHRM) ). PharmaTher Holdings Ltd. has received FDA approval for its ketamine ...

The FDA has approved Ketarx, a ketamine-based drug developed by drugmaker PharmaTher, for use in pain management. The medication is now cleared by the FDA for clinical use in perioperative settings, ...

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to ...

The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical ...

Detailed price information for Pharmather Hldgs Ltd (PHRM-CN) from The Globe and Mail including charting and trades.

PharmaTher Holdings Ltd ( ($TSE:PHRM) ) just unveiled an update. PharmaTher Holdings Ltd. has received FDA approval for its ketamine product, ...

PharmaTher has completed a preclinical study of its MDMA MN-Patch and plans to release the results early in the second quarter. The partners are already looking to the next steps, with Revive ...

PharmaTher expects to file its Abbreviated New Drug Application (ANDA) for KETARX with the FDA in early July and obtain the agency’s approval in the first quarter of 2024. Anticipating KETARX's ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and ...

"PharmaTher is committed to revolutionizing patient care through ketamine. With KetaVault™, PharmaTher isn't just sharing data; we're igniting a new era of collaborative ketamine innovation.

PharmaTher Holdings PHRRF and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes.